ArticleThoracic cancer2021

A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4 years by switching to ceritinib.

Yuki Matsumura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.